Chlormadinone acetate is effective for hot flush during androgen deprivation therapy

Hidekazu Koike, Yasuyuki Morikawa, Hiroshi Matsui, Yasuhiro Shibata, Kazuto Ito, Kazuhiro Suzuki

Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Japan

Purpose: To investigate the clinical efficacy of low-dose chlormadinone acetate (CMA) in prostate cancer patients who suffer from hot flushes that is a major side effect of androgen deprivation therapy.

Methods: Our study included 32 prostate cancer patients who had severe hot flush after undergoing hormone therapy for more than 3 months. The average age of the patients was 72.5 years. In the beginning, patients received CMA at 100 mg orally per day. We defined the hot flush as disappeared, improved, or not improved. In patients with disappeared or improved symptoms, we decreased CMA dose to 50 mg per day, and after we reevaluated the effect, we decreased CMA dose to 25 mg per day. When hot flush appeared again at 25 mg per day, we returned the dose of CMA to 50 mg per day. In cases with no change for more than two months, we canceled the treatment of CMA.

Results: Hot flush disappeared in 17 patients, improved in 10 patients, and did not improve in 5 patients (reduction in 84% of hot flush patients). The median time to hot flush reduction was 1.16 months. The effect of CMA was maintained at 25 mg per day in 19 patients and at 50 mg per day in 8 patients. No patients had prostate-specific antigen failure in the treatment of CMA.

Conclusions: When hot flush appears during treatment with luteinizing hormone-releasing hormone agonist for prostate cancer, it seems that CMA can improve it immediately in most patients.

Keywords: Hormonal antineoplastic agents, Chlormadinone acetate, Hot flashes, Prostate neoplasms

INTRODUCTION

Hot flush is a major side effect of androgen deprivation therapy for prostate cancer patients. Up to 80% of patients undergoing treatment with gonadotropin-releasing hormone (GnRH) analogues report hot flushes, and up to 27% report hot flushes as being the most troublesome side effect of treatment [1]. Although the pathophysiology of hot flush is incompletely understood, a number of effective therapies are available for its management. For example, there are transdermal estrogen patch [2] and megestrol acetate [3] amongst hormonal treatment options, and clonidine [4], gabapentin [5], and selective serotonin reuptake inhibitor (SSRI) [6] amongst nonhormonal treatment options.

Chlormadinone acetate (CMA) is a steroidal antiandrogen similar to progesterone used in maximum androgen blockade (MAB) therapy as well as monotherapy for prostate cancer in Japan. We investigated the clinical efficacy of low-dose CMA in prostate cancer patients who suffer from hot flushes.

MATERIALS AND METHODS

Our study included 32 prostate cancer patients who had severe hot flush after undergoing hormone therapy for more
than 3 months (Table 1). In 30 patients who had been treated with only luteinizing hormone-releasing hormone (LH-RH), CMA was administered. In 2 patients who had been treated with MAB using bicalutamide (and whose cancer control was good), bicalutamide was changed to CMA. The average age of the patients was 72.5 years. The mean of prostate-specific antigen (PSA) before LH-RH agonist treatment was 35.2 ng/mL. Clinical stages of the enrolled patients were T1–T2N0M0 in 24, T3N0M0 in 6, N1M0 in one, and M1 in one, respectively. The median time to hot flush appearing after initiating hormone therapy was 5.5 months. In the beginning, patients received CMA at 100 mg orally per day. One doctor evaluated the curative effect four weeks later. We defined the evaluation of hot flush as disappeared (the symptom disappeared when conscious), improved (the symptom improved when conscious), not improved (the symptom did not improve when conscious). In patients with disappeared or improved symptoms, we decreased CMA dose to 50 mg per day. Four weeks later, we reevaluated the effect, and we decreased CMA dose to 25 mg per day. When hot flush appeared again at 25 mg per day, we returned the dose of CMA to 50 mg per day. Basically, CMA treatment was continued as long as it was effective. In patients with no change for more than two months, we canceled the treatment of CMA. This study was approved by the Ethical Committee of Gunma University Hospital.

### RESULTS

Hot flush disappeared in 17 patients, was improved in 10 patients, was not improved in 5 patients (reduction in 84% of hot flush patients). The median time to hot flush reduction was 1.16 months. The effect of CMA was maintained at 25 mg per day in 19 patients and at 50 mg per day in 8 patients (Fig. 1). The role of ADT in the patients enrolled in this study and average duration of CMA in patients with response of CMA were shown in Table 2. No patients had PSA failure in the treatment of CMA. Adverse events were mild as shown in Table 3.

### DISCUSSION

A number of effective therapies are available for the management of hot flush [7]. Recently, Suzuki et al. [8] reported the clinical efficacy of milnacipran, serotonin-noradrenaline reuptake inhibitor (SNRI) in prostate cancer patients who suffer from hot flushes. It is reported that SNRI has a stronger effect for depression and less side effects in comparison with SSRI [9]. Their study included 12 patients who had taken hor-

### Table 1. The characteristics of the enrolled patients

| Characteristic                  | Value                                      |
|---------------------------------|--------------------------------------------|
| Age (yr), average (range)       | 72.5 (59–85)                               |
| Serum PSA (ng/mL)               |                                             |
| <10                             | 14                                         |
| 10–20                          | 10                                         |
| >20                            | 8                                          |
| Testosterone (ng/mL), average (range) | 4.16 (2.1–8.7)                           |
| Clinical stage                  |                                             |
| T1–T2N0M0                       | 24                                         |
| T3N0M0                          | 6                                          |
| N1M0                            | 1                                          |
| M1                              | 1                                          |
| Gleason score                   |                                             |
| 6                               | 3                                          |
| 7                               | 20                                         |
| 8                               | 2                                          |
| 9                               | 7                                          |
| Purpose of use of LH-RHa        |                                             |
| Monotherapy                     | 15                                         |
| Combination with radiation      | 15                                         |
| Salvage                         | 2                                          |

**Table 1.** The characteristics of the enrolled patients

**Table 2.** The average duration of the chlormadinone acetate (CMA) treatment in responsive case

| CMA treatment | Duration (mo), average (range) |
|---------------|-------------------------------|
| Monotherapy   | 26.8 (5–78)                   |
| Combination with radiation | 16.4 (3–76) |
| Salvage       | 14.2 (4–24)                   |

**Table 2.** The average duration of the chlormadinone acetate treatment

| Adverse events                  | No. (%) | Grade |
|---------------------------------|---------|-------|
| Hyperhidrosis                   | 1 (3.1) | 2     |
| ALT, AST increased              | 1 (3.1) | 2     |

**Table 3.** The adverse events of chlormadinone acetate treatment

**Fig. 1.** The effect of chlormadinone acetate (CMA).
mone therapy for at least 3 months prior to the trial entry. At 12 weeks, 9 patients were available for the evaluation. Four patients received 50 mg per day and 5 patients received 25 mg per day. The patients with ≥50% decrease in baseline hot flush score were observed in 3 out of 4 who received 50 mg and 2 out of 5 who received 25 mg per day. The frequency of hot flushes had significantly decreased at the 12 weeks period than the baseline in the milnacipran 50 mg per day treatment group. These results indicated that milnacipran 50 mg per day therapy is effective in the treatment of hot flushes.

A previous study showed that the effect was comparatively high with corpus luteum hormone drug [10]. Irani et al. [11] reported a multicenter, randomized, double-blind study to compare the efficacy of venlafaxine, cyproterone acetate, and medroxyprogesterone acetate for the treatment of hot flushes in patients with prostate cancer who were being treated with GnRH analogues. They concluded after 6 months of treatment that leuprorelin, venlafaxine, cyproterone, and medroxyprogesterone were effective in reducing hot flushes. However, the hormonal treatments cyproterone and medroxyprogesterone were significantly more effective than venlafaxine. As cyproterone is a recognised treatment in prostate cancer, and its use could interfere with hormonal therapy, medroxyprogesterone could be considered to be the standard treatment for hot flushes in men undergoing androgen suppression for prostate cancer. In Japan, Sakai et al. [12] undertook a prospective, randomized study to longitudinally examine the status of the development of hot flushes in, and quality of life of, Japanese patients with prostate cancer who underwent combined androgen blockade (CAB) with a steroidal or nonsteroidal antiandrogen. They reported that the median frequencies of hot flushes daily were 1.3 and 2.2 for warmth/flushing (P=0.16) and 1.0 and 3.6 for sweating (P=0.021) in the chlormadinone and bicalutamide groups, respectively. Patients in the chlormadinone group were significantly less likely to be distressed by warmth/flushing (odds ratio, 0.47; P<0.001) and sweating (odds ratio, 0.61; P=0.01) than those in the bicalutamide group. They concluded that CAB using a steroidal antiandrogen such as chlormadinone might induce fewer and less-distressing hot flushes than CAB with bicalutamide. These finding prompted us to use CMA for prostate cancer patients who had severe hot flush in during treatment with GnRH analogues. In this study, reduction in 84% of hot flush patients was observed. There are not many reports in which CMA was used for hot flush during treatment with GnRH analogue. Suzuki et al. [13,14] evaluated the incidence of hot flushes in sixty-eight prostate cancer patients receiving endocrine therapy. The overall incidence of hot flushes was 37%, and hot flushes improved after 4 weeks in 3 of 4 patients (75%) treated by CMA. They used CMA again for ten hot flush patients later. Hot flushes improved after 4 weeks in 9 of 10 patients (90%).

With regard to problems concerning the CMA dosage, using steroidal antiandrogen in MAB treatment has been identified as disadvantageous by meta-analysis [15,16]. The results for cyproterone acetate, which accounted for only a fifth of the evidence, appeared slightly unfavorable to MAB (5-year survival, 15.4% with MAB vs. 18.1% with androgen suppression [AS] alone; difference, –2.8% [standard error {SE}, 2.4]; log-rank, P=0.04 adverse), whereas those for nilutamide and flutamide appeared slightly favorable (5-year survival, 27.6% with MAB vs. 24.7% with AS alone; difference, 2.9% [SE, 1.3]; log-rank, P=0.005) [15], Sakai et al. [12] stated that, from the viewpoint of safety, chlormadinone, not cyproterone, was developed as a therapeutic drug for prostate cancer in Japan, but because their study had a limited duration of 2 years, the difference in survival time between the treatment groups was not assessed. Against such a background, we carried out gradual decrease of dose of CMA to avoid disadvantageous effects for prostate cancer treatment. Although the usual dose of CMA for prostate cancer is 100 mg/day, hot flush disappeared in all patients at 50 mg/day. Furthermore, the effect of CMA was maintained at 25 mg/day in many patients. In addition, no patients had PSA failure in the treatment of CMA. Considering the above, the gradual decrease of dose of CMA may be appropriate for treating hot flush.

The limitation of this study is the relative small number of enrolled patients, and the one-armed observation study. We are planning to add the number of patients, and to reevaluate the efficacy of CMA.

In conclusion, when hot flush appears during treatment with LH-RH agonist for prostate cancer, CMA might improve hot flush. If the effect of CMA is maintained, low dose CMA might be used.

**CONFLICT OF INTEREST**

No potential conflict of interest relevant to this article was reported.

**REFERENCES**

1. Holzbeierlein JM, McLaughlin MD, Thrasher JB. Complications of androgen deprivation therapy for prostate cancer. Curr Opin Urol 2004;14:177-83.

2. Gerber GS, Zagaja GP, Ray PS, Rukstalis DB. Transdermal
estrogen in the treatment of hot flushes in men with prostate cancer. Urology 2000;55:97-101.
3. Loprinzi CL, Michalak JC, Quella SK, O’Fallon JR, Hatfield AK, Nelimestone RA, et al. Megestrol acetate for the prevention of hot flushes. N Engl J Med 1994;331:347-52.
4. Loprinzi CL, Goldberg RM, O’Fallon JR, Quella SK, Miser AW, Mynderse LA, et al. Transdermal clonidine for ameliorating post-orchectomy hot flushes. J Urol 1994;151:634-6.
5. Jeffery SM, Pepe JJ, Popovich LM, Vitagliano G. Gabapentin for hot flushes in prostate cancer. Ann Pharmacother 2002;36: 433-6.
6. Loprinzi CL, Barton DL, Carpenter LA, Sloan JA, Novotny PJ, Gettman MT, et al. Pilot evaluation of paroxetine for treating hot flushes in men. Mayo Clin Proc 2004;79:1247-51.
7. Baum NH, Torti DC. Managing hot flushes in men being treated for prostate cancer. Geriatrics 2007;62:18-21.
8. Suzuki H, Komiya A, Kojima S, Tobe T, Ueda T, Ichikawa T. The clinical efficacy of SNRI milnacipran in the treatment of hot flushes with prostate cancer hormonally treated. Hinyokika Kiyo 2007;53:375-9.
9. Lopez-Ibor J, Guelfi JD, Pletan Y, Tournoux A, Prost JF. Milnacipran and selective serotonin reuptake inhibitors in major depression. Int J Clin Psychopharmacol 1996;11 Suppl 4:41-6.
10. Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H. Methodologic lessons learned from hot flash studies. J Clin Oncol 2001;19:4280-90.
11. Irani J, Salomon L, Oba R, Bouchard P, Mottet N. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol 2010;11:147-54.
12. Sakai H, Igawa T, Tsurusaki T, Yura M, Kusaba Y, Hayashi M, et al. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer. Urology 2009;73:635-40.
13. Suzuki K, Kobayashi M, Tokue A. Clinical evaluation of hot flushes developing during endocrine therapy for prostate carcinoma. Nihon Hinyokika Gakkai Zasshi 2003;94:614-20.
14. Suzuki K, Suzuki K, Terauchi F, Morita T. Clinical evaluation of treatment for hot flushes developing during endocrine therapy in patients with prostate cancer. Jpn J Clin Urol 2006;60:393-6.
15. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists’ Collaborative Group. Lancet 2000;355:1491-8.
16. Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002;95:361-76.